Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with paten ductus arterious (PDA)

T. F. Yeh, D. Raval, S. Pyati, S. Pildes

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Recent studies suggested that prostaglandins (PGs) may play a role in the pathogenesis of retinopathy of prematuriry (ROP). To evaluate if PGs inhibitor, indomethacin, would affect the incidence or severity of the ble-blind controlled study of indomethacin for the closure of PDA. Twenty-three were in the control group and 24 in the indometchin group. Indirect ophthalmospic examinations wee performed from about 4 weeks of postnatal age and onward and needed. There was no significant differences between the groups with respect to birth weight, gestational age, postnatal age, Apgar score, and cardiopulmonary status shortly after birth and at the time of study. Six in the control and 2 in the indomethacin group (p=0.58) developed active ROP; one in each group developed cicatricial ROP. It appears that with current doses of therapy, indomethacin does not increase the incidence or severity of ROP.

Original languageEnglish
Pages (from-to)385-391
Number of pages7
JournalProstaglandins
Volume25
Issue number3
DOIs
Publication statusPublished - Jan 1 1983
Externally publishedYes

Fingerprint

Retinopathy of Prematurity
Premature Infants
Indomethacin
Prostaglandin Antagonists
Time and Motion Studies
Apgar Score
Incidence
Therapeutics
Birth Weight
Gestational Age
Prostaglandins
Parturition
Control Groups

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with paten ductus arterious (PDA). / Yeh, T. F.; Raval, D.; Pyati, S.; Pildes, S.

In: Prostaglandins, Vol. 25, No. 3, 01.01.1983, p. 385-391.

Research output: Contribution to journalArticle

@article{98746b80bced4671b97b49b804f1bb23,
title = "Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with paten ductus arterious (PDA)",
abstract = "Recent studies suggested that prostaglandins (PGs) may play a role in the pathogenesis of retinopathy of prematuriry (ROP). To evaluate if PGs inhibitor, indomethacin, would affect the incidence or severity of the ble-blind controlled study of indomethacin for the closure of PDA. Twenty-three were in the control group and 24 in the indometchin group. Indirect ophthalmospic examinations wee performed from about 4 weeks of postnatal age and onward and needed. There was no significant differences between the groups with respect to birth weight, gestational age, postnatal age, Apgar score, and cardiopulmonary status shortly after birth and at the time of study. Six in the control and 2 in the indomethacin group (p=0.58) developed active ROP; one in each group developed cicatricial ROP. It appears that with current doses of therapy, indomethacin does not increase the incidence or severity of ROP.",
author = "Yeh, {T. F.} and D. Raval and S. Pyati and S. Pildes",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/0090-6980(83)90041-2",
language = "English",
volume = "25",
pages = "385--391",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "0090-6980",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with paten ductus arterious (PDA)

AU - Yeh, T. F.

AU - Raval, D.

AU - Pyati, S.

AU - Pildes, S.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Recent studies suggested that prostaglandins (PGs) may play a role in the pathogenesis of retinopathy of prematuriry (ROP). To evaluate if PGs inhibitor, indomethacin, would affect the incidence or severity of the ble-blind controlled study of indomethacin for the closure of PDA. Twenty-three were in the control group and 24 in the indometchin group. Indirect ophthalmospic examinations wee performed from about 4 weeks of postnatal age and onward and needed. There was no significant differences between the groups with respect to birth weight, gestational age, postnatal age, Apgar score, and cardiopulmonary status shortly after birth and at the time of study. Six in the control and 2 in the indomethacin group (p=0.58) developed active ROP; one in each group developed cicatricial ROP. It appears that with current doses of therapy, indomethacin does not increase the incidence or severity of ROP.

AB - Recent studies suggested that prostaglandins (PGs) may play a role in the pathogenesis of retinopathy of prematuriry (ROP). To evaluate if PGs inhibitor, indomethacin, would affect the incidence or severity of the ble-blind controlled study of indomethacin for the closure of PDA. Twenty-three were in the control group and 24 in the indometchin group. Indirect ophthalmospic examinations wee performed from about 4 weeks of postnatal age and onward and needed. There was no significant differences between the groups with respect to birth weight, gestational age, postnatal age, Apgar score, and cardiopulmonary status shortly after birth and at the time of study. Six in the control and 2 in the indomethacin group (p=0.58) developed active ROP; one in each group developed cicatricial ROP. It appears that with current doses of therapy, indomethacin does not increase the incidence or severity of ROP.

UR - http://www.scopus.com/inward/record.url?scp=0020638391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020638391&partnerID=8YFLogxK

U2 - 10.1016/0090-6980(83)90041-2

DO - 10.1016/0090-6980(83)90041-2

M3 - Article

VL - 25

SP - 385

EP - 391

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 0090-6980

IS - 3

ER -